Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

636 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.
Minozzi S, Bonovas S, Lytras T, Pecoraro V, González-Lorenzo M, Bastiampillai AJ, Gabrielli EM, Lonati AC, Moja L, Cinquini M, Marino V, Matucci A, Milano GM, Tocci G, Scarpa R, Goletti D, Cantini F. Minozzi S, et al. Among authors: scarpa r. Expert Opin Drug Saf. 2016 Dec;15(sup1):11-34. doi: 10.1080/14740338.2016.1240783. Expert Opin Drug Saf. 2016. PMID: 27924643 Free article. Review.
Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs.
Atteno M, Peluso R, Costa L, Padula S, Iervolino S, Caso F, Sanduzzi A, Lubrano E, Del Puente A, Scarpa R. Atteno M, et al. Among authors: scarpa r. Clin Rheumatol. 2010 Apr;29(4):399-403. doi: 10.1007/s10067-009-1340-7. Clin Rheumatol. 2010. PMID: 20066450 Clinical Trial.
Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study.
Spadaro A, Punzi L, Marchesoni A, Lubrano E, Mathieu A, Cantini F, Olivieri I, Salvarani C, Scarpa R, Scrivo R, Ramonda R, Porru G, D'Angelo S, Catanoso M, Atteno M, Valesini G. Spadaro A, et al. Among authors: scarpa r. Rheumatology (Oxford). 2010 Jun;49(6):1107-11. doi: 10.1093/rheumatology/keq008. Epub 2010 Mar 11. Rheumatology (Oxford). 2010. PMID: 20223813
Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for Rheumatology.
Salvarani C, Pipitone N, Marchesoni A, Cantini F, Cauli A, Lubrano E, Punzi L, Scarpa R, Spadaro A, Matucci-Cerinic M, Olivieri I; Italian Society for Rheumatology. Salvarani C, et al. Among authors: scarpa r. Clin Exp Rheumatol. 2011 May-Jun;29(3 Suppl 66):S28-41. Epub 2011 Jul 26. Clin Exp Rheumatol. 2011. PMID: 21906425 Review.
Etanercept in spondyloarthropathies. Part I: current evidence of efficacy.
Palazzi C, D'Angelo S, Cantini F, Lubrano E, Marchesoni A, Mathieu A, Salvarani C, Scarpa R, Spadaro A, Olivieri I. Palazzi C, et al. Among authors: scarpa r. Clin Exp Rheumatol. 2011 Sep-Oct;29(5):858-64. Epub 2011 Oct 31. Clin Exp Rheumatol. 2011. PMID: 22041180 Review.
636 results